2-formylphenyl 4-bromobutanoate | 937808-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 2-formylphenyl 4-bromobutanoate
• 英文别名: (2-Formylphenyl) 4-bromobutanoate
• CAS: 937808-67-8
• 化学式: C₁₁H₁₁BrO₃
• 分子量: 271.111
• InChiKey: AZIVEMDPCYAOAK-UHFFFAOYSA-N

物化性质

• 沸点：
  376.6±27.0 °C(Predicted)
• 密度：
  1.466±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-formylphenyl 4-bromobutanoate 在 potassium permanganate 、 silver nitrate 作用下， 以 丙酮 、 乙腈 为溶剂， 反应 15.0h， 生成 2-{[(4-nitroxy)butanoyl]oxy}benzoic acid
  参考文献：
  名称：

  NOSH-Aspirin: A Novel Nitric Oxide–Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals

  摘要：

  A series of new hybrids of aspirin (ASA), bearing both nitric oxide (NO) and hydrogen sulfide (H2S)-releasing moieties were synthesized and designated as NOSH compounds (1-4). NOSH-1 (4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl 24(4-(nitrooxy)butanoyl)oxy) benzoate); NOSH-2 (4-(nitrooxy)butyl (2-((4-(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy)carbonyl)phenyl)); NOSH-3 (4-carbamothioylphenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate); and NOSH-4 (4-(nitrooxy)butyl 2-(5-((R)-1,2-dithiolan-3-yl)pentanoyloxy)benzoate). The cell growth inhibitory properties of compounds 1-4 were evaluated in eleven different human cancer cell lines of six different tissue origins. These cell lines are of adenomatous (colon, pancreatic, lung, prostate), epithelial (breast), and lymphocytic (leukemia) origin. All NOSH compounds were extremely effective in inhibiting the growth of these cell lines. NOSH-1 was the most potent, with an IC50 of 48 +/- 3 nM in HT-29 colon cancer cells. This is the first NSAID-based compound with such potency. This compound was also devoid of any cellular toxicity, as determined by LDH release. NOSH-1 was comparable to aspirin in its anti-inflammatory properties, using the carrageenan rat paw edema model.

  DOI：

  10.1021/ml300002m
• 作为产物：
  描述：

  4-溴丁酸 、 水杨醛 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 2-formylphenyl 4-bromobutanoate
  参考文献：
  名称：

  NOSH-Aspirin: A Novel Nitric Oxide–Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals

  摘要：

  A series of new hybrids of aspirin (ASA), bearing both nitric oxide (NO) and hydrogen sulfide (H2S)-releasing moieties were synthesized and designated as NOSH compounds (1-4). NOSH-1 (4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl 24(4-(nitrooxy)butanoyl)oxy) benzoate); NOSH-2 (4-(nitrooxy)butyl (2-((4-(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy)carbonyl)phenyl)); NOSH-3 (4-carbamothioylphenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate); and NOSH-4 (4-(nitrooxy)butyl 2-(5-((R)-1,2-dithiolan-3-yl)pentanoyloxy)benzoate). The cell growth inhibitory properties of compounds 1-4 were evaluated in eleven different human cancer cell lines of six different tissue origins. These cell lines are of adenomatous (colon, pancreatic, lung, prostate), epithelial (breast), and lymphocytic (leukemia) origin. All NOSH compounds were extremely effective in inhibiting the growth of these cell lines. NOSH-1 was the most potent, with an IC50 of 48 +/- 3 nM in HT-29 colon cancer cells. This is the first NSAID-based compound with such potency. This compound was also devoid of any cellular toxicity, as determined by LDH release. NOSH-1 was comparable to aspirin in its anti-inflammatory properties, using the carrageenan rat paw edema model.

  DOI：

  10.1021/ml300002m

文献信息

• Salicylic Acid Derivatives
  申请人：Gasco Alberto

  公开号：US20080293781A1

  公开（公告）日：2008-11-27

  The present invention refers to O-acyl salicylic acid derivatives (I) bearing a NO donor moiety, a process for their preparation and pharmaceutical compositions containing them. (I) wherein: D is ONO 2 or (A).

  本发明涉及一种带有NO供体基团的O-酰基水杨酸衍生物(I)，以及它们的制备方法和含有它们的制药组合物。(I)式中：D为ONO2或（A）。
• NO- and H2S-releasing compounds
  申请人：RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK

  公开号：US10450260B2

  公开（公告）日：2019-10-22

  This disclosure relates to compounds containing both an NO-releasing moiety and an H2S-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.

  本公开涉及同时含有释放 NO 的分子和释放 H2S 的分子的化合物，以及此类化合物在治疗炎症性疾病（包括癌症）中的应用。
• NO- AND H2S- RELEASING COMPOUNDS
  申请人：Research Foundation Of The City University Of New York

  公开号：EP2744487B1

  公开（公告）日：2016-10-05
• [EN] NO- AND H2S- RELEASING COMPOUNDS<br/>[FR] COMPOSÉS LIBÉRANT NO ET H2S
  申请人：UNIV CITY NEW YORK RES FOUND

  公开号：WO2013025790A3

  公开（公告）日：2013-05-10
• Searching for New NO-Donor Aspirin-like Molecules: A New Class of Nitrooxy-acyl Derivatives of Salicylic Acid
  作者：Loretta Lazzarato、Monica Donnola、Barbara Rolando、Elisabetta Marini、Clara Cena、Gabriella Coruzzi、Elena Guaita、Giuseppina Morini、Roberta Fruttero、Alberto Gasco、Stefano Biondi、Ennio Ongini

  DOI：10.1021/jm701104f

  日期：2008.3.1

  A new class of products in which the phenol group of salicylic acid is linked to alkanoyl moieties bearing nitrooxy functions has been synthesized and studied for their polyvalent actions. The products were stable in acid and neutral media, while they were hydrolyzed in human serum. Their half-lives were dependent upon the structure of alkanoyl moieties. The products showed anti-inflammatory activities similar to aspirin when tested in the carrageenan-induced paw edema assay in the rat. Interestingly, unlike aspirin, they showed reduced or no gastrotoxicity in a lesion model in rats at equimolar doses. A number of them were able to inhibit platelet aggregation induced by collagen in human platelet-rich plasma. All of the products were capable of relaxing rat aortic strips precontracted with phenylephrine in a concentration-dependent manner. Selected members of this new class of nonsteroidal anti-inflammatory drugs might represent possible safer alternatives to aspirin in different clinical settings.